Healthcare • Drug Manufacturers - General
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ABBV is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
500 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 57 days ago
Red flags: 2
4,238 filers reported a long position in ABBV for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $37.6B | 149.5M | -0.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $29B | 115.4M | +0.4% |
| STATE STREET CORP | $20.8B | 82.6M | +1.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.2B | 48.5M | -2.1% |
| JPMORGAN CHASE & CO | $12.2B | 47.9M | -15.6% |
| GEODE CAPITAL MANAGEMENT, LLC | $11.8B | 47M | +0.6% |
| MORGAN STANLEY | $9.8B | 38.9M | +2.3% |
| Capital Research Global Investors | $7.6B | 30.1M | -3.7% |
| NORGES BANK | $6.4B | 25.6M | — |
| BANK OF AMERICA CORP /DE/ | $5.3B | 21.2M | -11.3% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.